Articles & Press Releases

Whichever instrument used – QALY or non-QALY – payers make evidence-based coverage decisions

In the face of scarce resources, healthcare entities must make hard choices. One can’t spend the same healthcare dollar twice, which means that policymakers have to ensure that each dollar goes as far as it can in terms of producing health outcomes for the population. Preferably decisions on how to allocate resources are informed by robust evidence that describes the benefits and harms related to medical interventions.

Adding a Medicare Part E benefit to pay for cell and gene therapies

Despite their curative potential, the extraordinarily high price tags of cell and gene therapies have raised concerns about the U.S. and European healthcare systems' financial sustainability. This is especially true for recently approved treatments indicated for relatively sizable sub-populations, including multiple myeloma, beta thalassemia, sickle cell disease and different types of hemophilia.

A novel Medicaid model to pay for latest gene therapies

Newly approved gene therapies for hemophilia A and B, beta thalassemia and sickle cell disease come with multimillion dollar price tags that could bankrupt financially strapped state Medicaid programs. In many instances, the majority of patients affected by these diseases rely on Medicaid for healthcare coverage.

Value-based insurance design is ready for primetime

Ostensibly, patients who have “skin in the game” through cost-sharing motivates them to be good stewards of their pharmacy benefit. But in the present system in the U.S., cost-sharing is usually not outcomes-based. It’s simply a way for insurers to defray costs onto patients, even when it poses barriers to access.

Re-dosable gene therapy Vyjuvek’s initially successful launch offers lessons

The promise of gene therapy is to cure diseases associated with faulty or missing genes. Yet the high upfront costs, uncertainty surrounding long-term durability, and adverse events in some patients have often impeded market uptake.

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Basel, Switzerland –28, January 2025 - Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformative collaboration with EVERSANA®, a leading provider of global commercial services to the life sciences industry, to revolutionize drug pricing and access through artificial intelligence-driven insights.

Lyfegen Secures additional CHF 5 Million in Series A Funding to Scale Its Drug Rebate Management Platform Globally

Basel, Switzerland / Boston, USA – December 11, 2024

A New Era in Canadian Healthcare: Lyfegen's CEO Discusses Groundbreaking Collaboration

In an industry often characterized by incremental changes, Girisha Fernando, the CEO and founder of Lyfegen, is making leaps. We sat down with Fernando to discuss the recent landmark partnership between Lyfegen and Newfoundland and Labrador Health Services—a collaboration that heralds a significant shift in the Canadian healthcare landscape.

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

Lyfegen Launches the World's Largest Database of Value-Based Drug Agreements

New York, NY - March 29, 2023 - Lyfegen, a global healthtech SaaS company driving the world’s transition from volume to value-based healthcare for high-cost drugs, announced at the World EPA Congress the launch of its latest solution: the Model & Agreement Library. The purpose of the library is to help payers and pharma negotiate better drug prices while providing an in-depth view on current international drug pricing models and value-based agreements. The database library serves as the basis for successful drug pricing negotiations, resulting in accelerated access and drug prices better aligned to their value for the patient.

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

We are thrilled to welcome Ina Hasani to our team at Lyfegen as Director of Sales & Business Development for Canada. Ina brings nearly a decade of experience in the life sciences sector, specializing in healthcare strategy, market access, and health economics. We sat down with Ina to learn more about her background, her vision for transforming healthcare in Canada, and what excites her most about joining Lyfegen.

A Fable of the Blue Bird and Lyfegen's Wise Owls

Once upon a time, In a whimsical forest, there lived a smart and creative blue bird. This bird, known for its brilliance in the world of tiny forest biotech, had concocted a magical potion.

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh perspective to our mission.

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

At this years World Evidence, Pricing and Access event, Girisha Fernando, the CEO of Lyfegen, expressed excitement as he spoke about the company’s latest launched offering - the Lyfegen Model & Agreement Library. This unique learning resource is a true game-changer that builds upon the company’s existing product. It expands our horizons by allowing payers and market access & pricing professionals to explore over 2’500 real-life public agreements, and 18 drug pricing models from around the world. The library provides an unparalleled understanding of drug reimbursement models that help users make better informed choices like never before.

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

He’s analytical, a techie and has a fantastic gift for music! Yes, we are talking about the latest addition to our team, our very own “Technical Business Analyst” and Ukrainian superstar: Pavlo Lupandin!

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

Gene therapies are redefining modern healthcare, offering the potential to address the root causes of genetic disorders through targeted treatment rather than symptom management. For patients, this represents a profound improvement in quality of life, while for payers and pharmaceutical companies, gene therapies introduce new challenges in contract structuring, reimbursement, and financial planning. In this blog, we’ll explore how gene therapies are reshaping patient outcomes, impacting payer expectations, and how Lyfegen’s solutions, such as the Agreements Library and Drug Contracting Simulator, are enabling pharma and payers to navigate this evolving landscape.

The role of value-based care in patient access

With rising healthcare costs around the world, value-based care (VBC) is a paradigm shift poised to make healthcare more accessible and affordable. It’s a departure from the traditional fee-for-service (FFS) model, which pays providers each time they perform a service. In this type of care model, providers are rewarded for the volume of care they provide, rather than the quality.

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

The pharmaceutical industry and its drug market access strategies are continuing to evolve as we move through 2024, driven by mounting pricing pressures, aggressive regulatory shifts, and heightened payer demands. For pharma companies, refining market access strategies is no longer optional—it’s essential to securing rapid market entry and sustained patient access in an increasingly challenging environment. Let’s explore the key considerations for pharma companies within this space.

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

The Joint Clinical Assessment (JCA) is poised to fundamentally change how health technologies gain market access across the European Union. Designed to streamline the evaluation process, the JCA promises to bring greater consistency, transparency, and efficiency to how new therapies and medical technologies are assessed for clinical effectiveness. But what does this mean for your market access strategies?

All the insights you need in one place.

On-Demand Insights

Rewriting the Playbook: ​ How AI Can Accelerate Market Access & Pricing Decisions​

2024 in Review: Are Drug Access Agreement Trends Going the Right Way?

Revolutionizing Drug Access in Portugal: Scaling Outcome-Based Agreements with Digital Innovation

Innovative Rebate Management in Oncology Drug Budgets

Articles & Press Releases

Whichever instrument used – QALY or non-QALY – payers make evidence-based coverage decisions

Whichever instrument used – QALY or non-QALY – payers make evidence-based coverage decisions

Adding a Medicare Part E benefit to pay for cell and gene therapies

Adding a Medicare Part E benefit to pay for cell and gene therapies

A novel Medicaid model to pay for latest gene therapies

A novel Medicaid model to pay for latest gene therapies

Value-based insurance design is ready for primetime

Value-based insurance design is ready for primetime

Re-dosable gene therapy Vyjuvek’s initially successful launch offers lessons

Re-dosable gene therapy Vyjuvek’s initially successful launch offers lessons

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights

Lyfegen Secures additional CHF 5 Million in Series A Funding to Scale Its Drug Rebate Management Platform Globally

Lyfegen Secures additional CHF 5 Million in Series A Funding to Scale Its Drug Rebate Management Platform Globally

A New Era in Canadian Healthcare: Lyfegen's CEO Discusses Groundbreaking Collaboration

A New Era in Canadian Healthcare: Lyfegen's CEO Discusses Groundbreaking Collaboration

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

Lyfegen Launches the World's Largest Database of Value-Based Drug Agreements

Lyfegen Launches the World's Largest Database of Value-Based Drug Agreements

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

A Fable of the Blue Bird and Lyfegen's Wise Owls

A Fable of the Blue Bird and Lyfegen's Wise Owls

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

The role of value-based care in patient access

The role of value-based care in patient access

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

Rewriting the Playbook: How AI Can Accelerate Market Access & Pricing Decisions